Nations Financial Group Inc. IA ADV Has $1.91 Million Position in Eli Lilly and Company (NYSE:LLY)

Nations Financial Group Inc. IA ADV reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 60.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,474 shares of the company’s stock after selling 3,730 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Eli Lilly and Company were worth $1,911,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB raised its position in shares of Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares during the period. Values Added Financial LLC increased its holdings in Eli Lilly and Company by 4.9% in the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after buying an additional 17 shares during the period. RFG Advisory LLC increased its holdings in Eli Lilly and Company by 7.6% in the 3rd quarter. RFG Advisory LLC now owns 9,006 shares of the company’s stock valued at $7,979,000 after buying an additional 635 shares during the period. Madrona Financial Services LLC increased its holdings in Eli Lilly and Company by 12.4% in the 3rd quarter. Madrona Financial Services LLC now owns 282 shares of the company’s stock valued at $250,000 after buying an additional 31 shares during the period. Finally, CHB Investment Group LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $2,764,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LLY. Barclays reduced their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Bank of America reissued a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup lowered their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company lowered their target price on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Finally, Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Trading Down 3.1 %

NYSE LLY opened at $844.82 on Friday. The company has a market cap of $802.01 billion, a PE ratio of 72.15, a PEG ratio of 1.87 and a beta of 0.42. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The stock has a 50 day moving average of $794.44 and a 200-day moving average of $844.60.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.71%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 44.41%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.